| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥54.2B | ¥47.3B | +14.7% |
| Operating Income | ¥3.3B | ¥4.5B | -26.2% |
| Ordinary Income | ¥3.2B | ¥4.8B | -32.2% |
| Net Income | ¥2.2B | ¥2.8B | -21.7% |
| ROE | 6.0% | 8.8% | - |
FY2026 Q3 cumulative results show revenue of 54.2B yen (YoY +14.7%), operating income of 3.3B yen (-26.2%), ordinary income of 3.2B yen (-32.2%), and net income of 2.2B yen (-21.7%). While top-line growth continues driven by DX segment expansion (+599.5%) and LifeScienceAI (+141.7%), operating profitability deteriorated significantly due to SG&A expense growth outpacing revenue gains. The company maintains a mixed performance pattern of revenue growth with profit decline, reflecting the impact of expansion investments and M&A integration costs.
Revenue increased 6.95B yen YoY to 54.2B yen, primarily driven by the DX segment which surged from 2.7B yen to 18.7B yen following the acquisition of Alnetz, and LifeScienceAI which expanded from 2.1B yen to 5.2B yen on accelerated AI drug discovery initiatives. The RiskManagement segment, while remaining the largest revenue contributor at 30.4B yen (56.0% of total), contracted 28.5% YoY as legal tech AI and compliance support demand softened. Gross profit margin remained robust at 49.8%, down modestly from prior period, indicating stable service delivery economics. However, operating income declined 1.2B yen to 3.3B yen as SG&A expenses expanded to 23.7B yen (43.6% of revenue) from 22.3B yen, reflecting personnel costs for business expansion, M&A integration expenses, and R&D investments in AI platforms. Non-recurring factors included impairment loss of 14M yen on discontinued software in DX segment and goodwill recognition of 1,253M yen from Alnetz acquisition. The gap between operating income (3.3B yen) and ordinary income (3.2B yen) was minimal at 100M yen, with non-operating income of 812M yen (primarily dividend income 433M yen and FX gains 150M yen) offset by non-operating expenses of 873M yen (interest expense 332M yen and commission fees 195M yen). Extraordinary items net impact was negative 9M yen. Net income of 2.2B yen reflects effective tax rate of 29.7%. Comprehensive income surged to 7.1B yen driven by unrealized gains on investment securities of 4.6B yen, significantly exceeding net income. This represents a revenue up/profit down pattern driven by expansion investments and segment mix shift.
LifeScienceAI segment posted revenue of 5.2B yen with operating loss of 2.3B yen (margin -45.4%), as AI drug discovery and medical device businesses remain in investment phase. The AI drug discovery subsegment grew to 3.8B yen while AI medical device contracted slightly to 1.3B yen. DX segment achieved revenue of 18.7B yen with operating income of 1.4B yen (margin 7.3%), representing dramatic expansion from prior period on Alnetz consolidation which contributed 16.7B yen in system development services. Operating profit improved to positive territory from prior losses on scale benefits. RiskManagement segment, the core business contributing 56.0% of total revenue, recorded 30.4B yen in sales with operating income of 4.3B yen (margin 14.2%). Within this segment, legal tech AI declined to 16.5B yen from 28.5B yen, while BI compliance support and economic security subsegments remained relatively stable. Operating profit decreased 1.4B yen YoY despite maintaining the highest margin among segments. The segment contribution shifted notably with DX rising from negligible to 34.5% of revenue and RiskManagement declining from 89.9% to 56.0%, indicating successful portfolio diversification but also highlighting dependence on high-margin RiskManagement for overall profitability.
[Profitability] ROE of 6.0% underperforms industry median of 8.3%, reflecting capital efficiency challenges as net profit margin compressed to 4.1% (industry median 6.0%) and operating margin declined to 6.1% (vs industry median 8.2%). The company's profitability deteriorated across metrics with DuPont analysis showing net margin of 4.1%, asset turnover of 0.607x, and financial leverage of 2.42x combining to generate the 6.0% ROE. Return on invested capital of 4.8% falls significantly below the healthy range of 7-8%, signaling inadequate return on deployed capital. [Cash Quality] Cash and deposits stand at 21.3B yen providing 0.93x coverage of short-term debt (23.0B yen short-term loans plus 4.9B yen current portion of long-term debt), indicating constrained near-term liquidity. Working capital of 1.1B yen represents only 2.6% of current assets. [Investment Efficiency] Asset turnover of 0.607x aligns closely with industry median of 0.67x but reflects capital intensity from intangible asset buildup. Total assets expanded to 89.4B yen from 64.7B yen, with intangible assets reaching 22.6B yen including goodwill of 12.0B yen and software of 6.2B yen. [Financial Health] Equity ratio of 41.4% trails industry median of 59.2%, positioning below the conservative 50% threshold. Current ratio of 102.7% (vs industry median 215%) signals elevated short-term liquidity risk. Debt-to-equity ratio stands at 1.42x with interest-bearing debt totaling 33.5B yen, comprising 23.0B yen short-term borrowings and 10.5B yen long-term debt. Debt-to-capital ratio of 47.5% exceeds the conservative 40% benchmark. Interest coverage ratio of 10.0x provides adequate buffer for debt service obligations. The short-term debt ratio of 68.8% creates refinancing risk concentration.
Cash and deposits increased 4.7B yen from prior fiscal year-end to 21.3B yen despite operating profit growth, as working capital movements and investment activities absorbed liquidity. The increase in trade payables to 1.2B yen from 0.2B yen suggests improved supplier credit utilization contributing 1.0B yen in working capital financing. Investment securities expanded significantly by 8.5B yen to 18.2B yen, indicating substantial deployment into financial assets. Intangible assets grew 14.3B yen including goodwill recognition of 1.3B yen from Alnetz acquisition and software capitalization of 3.8B yen, reflecting ongoing R&D and platform development investments. On the financing side, short-term borrowings surged 13.0B yen to 23.0B yen while long-term debt increased 7.6B yen to 10.5B yen, providing 20.6B yen net financing inflow to fund expansion activities. Retained earnings improved modestly by 2.3B yen to 1.2B yen, moving from accumulated deficit to positive territory. The cash coverage of short-term liabilities at 0.93x indicates limited buffer, warranting close monitoring of refinancing arrangements. The substantial increase in investment securities concurrent with borrowing expansion suggests strategic asset allocation rather than pure operational cash accumulation.
Ordinary income of 3.2B yen compared to operating income of 3.3B yen shows net non-operating contribution of negative 100M yen. Non-operating income totaled 812M yen, comprising dividend income of 433M yen (53% of non-operating income), FX gains of 150M yen, and subsidy income of 191M yen as primary components. Non-operating expenses of 873M yen consisted mainly of interest expense 332M yen and commission fees 195M yen. The non-operating net represents 1.8% of revenue, a modest proportion suggesting core operating performance drives results. Extraordinary items totaled net negative 9M yen from impairment loss of 14M yen and asset disposal losses offset partially by gain on reversal of subscription rights. Operating cash flow data is not disclosed in quarterly filings, limiting assessment of accruals quality. However, comprehensive income of 7.1B yen significantly exceeded net income of 2.2B yen, driven by unrealized gains on securities of 4.6B yen, indicating substantial mark-to-market valuation gains in investment portfolio that do not reflect cash earnings. The divergence between comprehensive income and net income warrants attention to earnings quality as approximately 69% of comprehensive income derives from non-cash valuation adjustments.
The company maintains full-year guidance of revenue 77.0B yen (YoY +26.2%), operating income 7.0B yen (+32.7%), and ordinary income 7.2B yen (+31.5%). Q3 cumulative progress rates stand at 70.4% for revenue, 47.4% for operating income, and 45.1% for ordinary income against full-year targets. Revenue progress tracking slightly above the standard 75% marker for Q3 reflects seasonality and growth momentum. However, operating income progress of 47.4% falls significantly below the 75% standard, requiring 3.7B yen operating profit generation in Q4 alone to achieve guidance, representing a 4.3x acceleration from Q3 run rate. This implies substantial Q4 profit improvement assumptions through revenue acceleration in high-margin RiskManagement recovery, cost absorption benefits from DX scale-up, and LifeScienceAI narrowing losses. The significant backend loading of profit expectations presents execution risk. The company disclosed Alnetz acquisition generated goodwill of 1,253M yen with purchase price allocation still provisional, creating uncertainty in final goodwill recognition. No forecast revisions were made this quarter, suggesting management confidence in Q4 performance trajectory despite current shortfalls.
Annual dividend remains zero yen for both interim and year-end, continuing the no-dividend policy. With net income of 2.2B yen and zero dividend payout, the payout ratio is 0%, indicating full retention of earnings for growth investments. No share buyback activities were disclosed during the period. The company prioritizes internal capital deployment toward business expansion, M&A integration, and R&D investments over shareholder distributions. The total return ratio including both dividends and buybacks stands at 0%. Retained earnings turned positive at 1.2B yen from accumulated deficit of 1.0B yen in prior year, suggesting gradual capital base rebuilding. Given the growth investment phase, expansion of intangible assets to 22.6B yen, and acquisition activities generating 12.0B yen goodwill, the zero-dividend policy appears consistent with capital allocation priorities favoring reinvestment over distribution.
Business concentration risk remains elevated with RiskManagement segment contributing 56.0% of revenue and 129.5% of total operating profit (offsetting losses in LifeScienceAI). Demand weakness in legal tech AI subsegment which contracted 42.0% YoY demonstrates vulnerability to specific vertical market conditions. Any further deterioration in core RiskManagement performance would directly impact consolidated profitability. Intangible asset and goodwill impairment risk intensified with goodwill reaching 12.0B yen (32.4% of equity) and total intangible assets of 22.6B yen following Alnetz acquisition. The DX segment already recorded 14M yen impairment on discontinued software this period. If revenue synergies or cost integration benefits from acquisitions underperform expectations, significant impairment charges could materialize. The company disclosed goodwill allocation remains provisional, creating additional uncertainty. Refinancing and liquidity risk stems from short-term debt concentration at 68.8% of total borrowings, with 23.0B yen short-term loans requiring rollover within 12 months while cash coverage stands at only 0.93x. Interest rate increases or credit tightening could elevate refinancing costs or constrain access to credit facilities, pressuring already compressed margins. The debt-to-capital ratio of 47.5% limits additional leverage capacity for growth funding.
[Industry Position] (Reference - Proprietary Analysis)
FRONTEO's financial positioning reveals several areas of underperformance relative to IT and telecommunications sector peers. Profitability metrics lag industry standards with ROE of 6.0% below the median of 8.3%, operating margin of 6.1% trailing the 8.2% median, and net profit margin of 4.1% versus 6.0% median. The company's return on assets of 2.5% (calculated from net income 2.2B/total assets 89.4B) falls below the sector median of 3.9%. Financial health indicators show concerning divergence with equity ratio of 41.4% substantially below the industry median of 59.2%, and current ratio of 102.7% dramatically lower than the 215% median, signaling elevated financial risk. Revenue growth of 14.7% exceeds the industry median of 10.4%, demonstrating superior top-line expansion driven by M&A and organic growth in DX and LifeScienceAI segments. However, this growth has not translated to competitive profitability, reflecting investment phase characteristics. Asset turnover of 0.607x approximates the 0.67x median, showing comparable capital efficiency in revenue generation. The company's financial leverage of 2.42x exceeds the median of 1.66x, consistent with the lower equity ratio and higher debt utilization strategy. EPS growth of negative 21.6% YoY significantly underperforms the industry median of 22.0% positive growth, highlighting earnings pressure from expansion investments.
※ Industry: IT and Telecommunications (104 companies), Comparison: 2025-Q3 Period, Source: Proprietary analysis
Portfolio transformation underway with DX segment emerging as significant growth driver, expanding from negligible contribution to 34.5% of revenue through Alnetz acquisition while maintaining positive 7.3% operating margin. This diversification reduces historical over-dependence on RiskManagement segment, though execution risk remains in achieving projected synergies and the company recorded immediate 14M yen impairment on acquired software assets. Profitability compression requires close monitoring as operating margin declined to 6.1% from 9.5% YoY despite revenue growth, driven by SG&A expense expansion to 43.6% of revenue. Management's ability to leverage scale benefits and rationalize costs in coming quarters will determine whether margin pressure is transitional investment-phase phenomenon or structural deterioration. The substantial gap between comprehensive income (7.1B yen) and net income (2.2B yen) creates earnings quality considerations, with 4.6B yen or 69% of comprehensive income derived from unrealized securities gains rather than operating cash generation. Short-term liquidity positioning warrants priority attention with cash-to-short-term-debt coverage of only 0.93x and current ratio of 102.7% far below industry norms, creating refinancing dependency. The 13.0B yen increase in short-term borrowings and elevated 68.8% short-term debt ratio amplify sensitivity to credit market conditions and interest rate movements.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.